A study of more than 14,000 lung cancer patients suggests age influences tumor biology and the availability of targeted therapy options.
RT’s Three Key Takeaways:
- Actionable Alterations: Younger patients with non-small cell lung cancer are significantly more likely to have genetic alterations that can be matched with targeted therapies than older patients.
- Tumor Biology: Research indicates a gradual shift in tumor biology across the lifespan, with older patients showing higher tumor mutational burden and different immune markers.
- Screening Guidelines: These findings may help identify high-risk populations and inform future efforts to refine screening guidelines for earlier lung cancer detection.
Younger adults with non-small cell lung cancer (NSCLC) are significantly more likely than older patients to have genetic alterations that can be matched with targeted therapies, according to findings to be presented at the 2026 World Conference on Lung Cancer
according to an international study led by researchers at Sylvester Cancer Center, part of the University of Miami Miller School of Medicine.
The study, which analyzed genomic and immune data from 14,246 patients, found that nearly 58% of younger patients had guideline-recommended actionable alterations. In contrast, approximately 45% of patients age 55 and older had similar alterations.
“As precision medicine continues to evolve, we need to think beyond identifying individual mutations and begin understanding the broader biologic context in which those mutations occur,” said Chinmay T Jani, medical oncologist at Sylvester and lead author of the study, in a news release. “Our findings suggest that age may be an important piece of that puzzle. By better understanding how tumors change across the lifespan, we can continue refining how we interpret biomarkers, develop new therapies and personalize treatment strategies for patients with lung cancer.”
suggest that age is a factor in understanding tumor biology and tailoring treatment. Older patients showed a different pattern, as their tumors were more likely to have KRAS-related changes and a higher tumor mutational burden, meaning the cancer carried more mutations overall.
“Age should be considered alongside traditional biomarkers when evaluating treatment options for patients with lung cancer,” said Gilberto Lopes, chief of medical oncology at Sylvester and senior author of the study, in a news release. “As we learn more about the factors that influence how individual tumors behave, we can make more informed treatment decisions and continue advancing truly personalized cancer care.”
The researchers also identified age-related differences in immune markers, including LAG3 and TIGIT. These markers are currently being studied as possible targets for future immunotherapy strategies. The study supports the use of genomic profiling for younger adults diagnosed with NSCLC to identify genetic drivers that may respond to targeted therapy.
Since younger adults generally fall outside current lung cancer screening eligibility criteria, the study authors noted that this research could help identify high-risk populations. This information may inform future efforts to refine screening guidelines to support earlier detection and improve healthcare outcomes for younger patients.
